Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 4Pancreatic Neoplasms 4Melanoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma 2Glioblastoma 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Xeroderma Pigmentosum 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Papillomavirus Infections 1Neuroblastoma 1

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Xeroderma Pigmentosum × Specimen Handling × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡